Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.
Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.
复制标题
伴随RRx-001与复发性小细胞癌中重新引入铂类化疗的II期试验的生物标志物研究结果。
DOI：
10.1080/13543784.2021.1863947
复制
发表时间：
2021-03
影响因子：
6.1
通讯作者：
Trepel, Jane B.
中科院分区：
文献类型：
--
作者：
Lee, Min-Jung;Tomita, Yusuke;Yuno, Akira;Lee, Sunmin;Abrouk, Nacer E.;Oronsky, Bryan;Caroen, Scott;Trepel, Jane B.
关键词：
在一项II期研究中，RRx-001与依托泊苷铂（EP）联合治疗既往接受过铂治疗的SCLC。我们将HLA-DR低/-单核细胞上的M2标记物CD 206的表达（与不良预后相关的表型）与对RRx-001的应答相关联。患者每周一次接受4 mg RRx-001，直至进展，随后开始EP（在21天周期的第1-3天IV给予依托泊苷100 mg/m2，在第1天IV给予顺铂80 mg/m2或在第1天IV给予卡铂AUC 5-6）。治疗持续至疾病进展或出现不可耐受的毒性。在筛选期间和第1、8和15天治疗后，采集14例患者的外周血，置于含柠檬酸钠的细胞制备管中进行探索性研究。通过离心从血液中分离外周血单个核细胞（PBMC），并进行多参数流式细胞术分析。HLA-DR低/-单核细胞上的CD 206表达与对化疗的反应和总生存率相关。在用RRx-001治疗期间，外周单核细胞上的促肿瘤发生M2标记物CD 206的表达降低与增加的应答和存活正相关。
In a Phase II study RRx-001 was combined with Etoposide platinum (EP) in previously platinum treated SCLC. We correlated expression of the M2 marker, CD206, on HLA-DRlow/- monocytes, a phenotype that correlates with a poor prognosis, with response to RRx-001. Patients received 4 mg RRx-001 once weekly until progression followed by the start of EP (etoposide 100 mg/m2 IV on days 1–3 of a 21-day cycle and either cisplatin 80 mg/m2 IV on day 1 or carboplatin AUC 5–6 IV on day 1). Treatment continued until progression or intolerable toxicity. Peripheral blood was collected in Cell Preparation Tubes with sodium citrate from 14 patients for exploratory studies during screening and after therapy on Days 1, 8, and 15. Peripheral blood mononuclear cells (PBMCs) were isolated from blood by centrifugation and multiparameter flow cytometric analysis was performed. CD206 expression on HLA-DRlow/- monocytes was associated with response to chemotherapy and overall survival. During treatment with RRx-001, reduced expression of the protumorigenic M2 marker CD206 on peripheral monocytes positively correlated with increased response and survival.
登录
查看更多内容
影响因子：
0.8
作者：
Carter, Corey A.;Oronsky, Bryan T.;Brzezniak, Christina
通讯作者：
Brzezniak, Christina
一种新型的缺氧选择性表观遗传剂RRX-001触发凋亡并克服了多发性骨髓瘤细胞中的耐药性。
影响因子：
11.4
作者：
Das DS;Ray A;Das A;Song Y;Tian Z;Oronsky B;Richardson P;Scicinski J;Chauhan D;Anderson KC
通讯作者：
Anderson KC
影响因子：
8.8
作者：
Morgensztern, Daniel;Rose, Michal;Padda, Sukhmani K.
通讯作者：
Padda, Sukhmani K.
影响因子：
6.1
作者：
Oronsky, Bryan;Paulmurugan, Ramasamy;Carterg, Corey A.
通讯作者：
Carterg, Corey A.
DOI：
10.1007/s00432-017-2416-4
发表时间：
2017-09-01
影响因子：
3.6
作者：
Oronsky, Bryan;Reid, Tony R.;Cabrales, Pedro
通讯作者：
Cabrales, Pedro